ATOS

Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference

Retrieved on: 
Wednesday, May 18, 2022
ATOS, U.S. Securities and Exchange Commission, Breast cancer, Nasdaq, Atossa, Infection, Form 10-K, Therapy, Fontainebleau Miami Beach, COVID-19, Breast, FDA, Conference, Forward-looking statement, Safety, General counsel, Security (finance), GLOBE, Pharmaceutical industry

SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that Kyle Guse, Chief Financial Officer and General Counsel, will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference.

Key Points: 
  • SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that Kyle Guse, Chief Financial Officer and General Counsel, will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference.
  • The conference is being held on May 23 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL.
  • Mr. Guse will be available for one-on-one meetings.
  • For more information, please visit www.atossatherapeutics.com .

Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 9, 2022
COVID-19, U.S. Securities and Exchange Commission, Forward-looking statement, Breast, IND, Nasdaq, Woman, GLOBE, Company, Breast cancer, Safety, Patient, Trial of the century, Security (finance), FDA, Patent, ATOS, CRO, Form 10-K, R, Method, Infection, Research, Acquisition, Therapy, Pharmaceutical industry, Video game, Endoxifen, Atossa, G&A

SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended March 31, 2022, and provides an update on recent company developments.

Key Points: 
  • SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended March 31, 2022, and provides an update on recent company developments.
  • The Company anticipates submitting an IND to the FDA in the second quarter of 2022.
  • For the quarter ended March 31, 2022, Atossa has no source of sustainable revenue and no associated cost of revenue.
  • Other compensation also increased $264 due to the addition of a new employee quarter over quarter as well as salary, bonus and benefit increases.

Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

Retrieved on: 
Wednesday, April 20, 2022
Breast, U.S. Securities and Exchange Commission, COVID-19, Security (finance), ATOS, B cell, Medicare, GLOBE, Patient, Form 10-K, Infection, Vaccine, Nasdaq, Breast cancer, Atossa, Forward-looking statement, Coronavirus, Safety, FDA, Severe acute respiratory syndrome coronavirus 2, Therapy, Pharmaceutical industry

SEATTLE, April 20, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces it has completed enrolling participants in Part B of its Phase 1/2a clinical study of AT-H201 in Australia, consisting of multiple ascending dose cohorts in healthy participants. AT-H201 is being developed as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease.

Key Points: 
  • Despite widespread availability of vaccines, many areas of the world are seeing a recent surge in COVID-19 cases.
  • The Phase 1/2a placebo-controlled study will enroll a total of 60 healthy participants and moderately-ill hospitalized COVID-19 patients.
  • Parts A, B and C of the study are being conducted by Avance Clinical Pty Ltd., a leading Australian clinical research organization.
  • Commencing Parts C and D of the study is subject to additional approvals from the Australian Human Research Ethics Committee.

Secure Open Source 5G Gains Momentum as Community Focuses on Re-aggregation, with 5G Super-Blueprints and New Members

Retrieved on: 
Tuesday, April 12, 2022
Cloud, RAN, Node.js, Housing, Regal, LTE, Linux Foundation, Foundation, Adoption, Executive Orders, OEM, Telco, Automation, MEC, Silver, Outline, ATOS, LFN, Linux, Organization, ONAP, EMCO, Open Networking Foundation, Enterprise, Denial-of-service attack, Technology, Keysight, Red fluorescent protein, Digital transformation, Ecosystem, Solution, Walmart, White House, Firewall (computing), Bill of materials, Digital, IOT, Open Source Security Foundation, Industry, Container, Network equipment, Renewable energy, Risk management, Magma, Telecom, Atos

The 5G Super Blueprint is now integrated across even more projectsincluding Magma (1.6), EMCO, and Anuketbuilding open source components applicable to a variety of industry use cases.

Key Points: 
  • The 5G Super Blueprint is now integrated across even more projectsincluding Magma (1.6), EMCO, and Anuketbuilding open source components applicable to a variety of industry use cases.
  • Preliminary scoping for future integrations with the O-RAN Software Community have begun, setting the stage for end-to-end open source interoperability from the core through the RAN and future compliance activities.
  • Telaverge's open source based private LTE and 5G cores are pre-integrated with Regal for zero touch testing and deployment.
  • Founded in 2000, the Linux Foundation is supported by more than 2,000 members and is the world's leading home for collaboration on open source software, open standards, open data, and open hardware.

Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference

Retrieved on: 
Wednesday, March 23, 2022
Maxim, Therapy, ATOS, Form 10-K, Forward-looking statement, Atossa, CFO, Conference, CEO, U.S. Securities and Exchange Commission, Security (finance), Safety, Infection, General counsel, Nasdaq, COVID-19, GLOBE, FDA, Breast cancer, Pharmaceutical industry

SEATTLE, March 23, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that management will participate at the Maxim Group 2022 Virtual Growth Conference, which is being held March 28-30, 2022.

Key Points: 
  • SEATTLE, March 23, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that management will participate at the Maxim Group 2022 Virtual Growth Conference, which is being held March 28-30, 2022.
  • Dr. Steven Quay, President and CEO and Kyle Guse, CFO and General Counsel will present a corporate overview which will become available on Monday, March 28, 2022 at 9:00am ET.
  • Investors can view the presentation on the investor relations section of the Companys web site beginning on March 28, 2022 or by registering for the conference here .
  • Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious diseases with a current focus on breast cancer and COVID-19.

Report from Cloudreach, an Atos Company, Reveals More Than 70% of Organizations Impacted by Cloud Skills Shortage

Retrieved on: 
Tuesday, March 22, 2022
Professional Services, Data Management, Technology, Human Resources, Mobile, Wireless, Software, Networks, Cloud, Microsoft, Organization, Microsoft Azure, Societas Europaea, Group, Society, SE, CAC, Growth, Business, Euronext Paris, CO2, ESG, Research, CEO, Carbon, Azure, View, IDC, Industry, Google Cloud, Knowledge, Digital, Amazon Web Services, EMEA, Solution, AWS, CAC Next 20, Efficiency, Education, World Economic Forum, Public relations, Video game console, Creative industries, Renewable energy, Atos, Cloudreach, CLOUDREACH, ATOS

Low supply of cloud skills is also hitting innovation, causing high staff turnover and wage inflation.

Key Points: 
  • Low supply of cloud skills is also hitting innovation, causing high staff turnover and wage inflation.
  • Multi-cloud capabilities, cloud system development, and cloud governance were the top three areas most impacted by the skills gap, according to respondents.
  • This research confirms that there is a shortage of cloud talent today, threatening cloud transformation projects that are essential to business survival, said Brooks Borcherding, CEO, Cloudreach.
  • The concern about the skills gap remained consistent across cloud organizations in both North America and Europe.

Cloudreach, an Atos Company, Works With AWS to Launch Talent Academy in the U.S.

Retrieved on: 
Friday, March 11, 2022
Technology, Human Resources, Security, Professional Services, Networks, Internet, Training, Data Management, Education, Cloud, CAC, Industry, Marketing, Research, Euronext Paris, ESG, Education, AWS, Societas Europaea, Amazon Web Services, Woman, Atlanta metropolitan area, Learning, Group, Cloud computing, Technology, Solution, Knowledge, CAC Next 20, SE, Organization, Program, Engineering, Society, Latinx, Medicine, Creative industries, Atos, Cloudreach, Certification, Talent Academy, Cloudreach, Atos, TALENT ACADEMY, CLOUDREACH, ATOS

Cloudreach, an Atos company, the leading multi-cloud services provider, today announced the launch of the Cloudreach Talent Academy in Atlanta.

Key Points: 
  • Cloudreach, an Atos company, the leading multi-cloud services provider, today announced the launch of the Cloudreach Talent Academy in Atlanta.
  • Were excited to be kicking off in Atlanta, a region full of untapped talent in technology, said Poonam Flammarion, Head of Talent Academy.
  • Through Talent Academy, Cloudreach and AWS want to help diversify the information technology industry by expanding its talent pool.
  • Cloudreach Talent Academy is an immersive program of accelerated, hands-on learning, intended to help diverse candidates launch their technical career in cloud computing.

Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen

Retrieved on: 
Tuesday, March 8, 2022
Risk, Breast, Patient, Woman, Patent, Forward-looking statement, Security (finance), Breast cancer, Safety, U.S. Securities and Exchange Commission, MBD, Infection, ER, FDA, American Cancer Society, Therapy, Method, ATOS, COVID-19, Disease, United States patent law, IND, Nasdaq, Incidence, GLOBE, Form 10-K, Pharmaceutical industry, Medical imaging, Endoxifen, Atossa

11,261,151 (the 151 Patent) is titled Methods for Making and Using Endoxifen and is directed to compositions of storage-stable Endoxifen and methods of treating hormone-dependent breast disorders using the storage-stable Endoxifen.

Key Points: 
  • 11,261,151 (the 151 Patent) is titled Methods for Making and Using Endoxifen and is directed to compositions of storage-stable Endoxifen and methods of treating hormone-dependent breast disorders using the storage-stable Endoxifen.
  • We are very pleased with the scope and breadth of this new key patent, said Dr. Steven Quay, Atossas President and Chief Executive Officer.
  • Patents covering the composition of matter of new therapies are critical to protect markets from generic competition.
  • The 151 Patent, with its estimated expiration in 2038, strengthens our intellectual property estate and should create long-term stockholder value.

IoT in Manufacturing Market growing at a CAGR of 14.50% over 2022-2032, at to reach USD 399.08 billion by 2026, Says FMI

Retrieved on: 
Wednesday, March 2, 2022
PTC, Adoption, Schneider Electric, IO, Software, Siemens, Computer, Machine learning, Automation, Research, SAP, Internet, Solution, Government, Safety, Aviation, Component, Boston, Bosch, FMI, ATOS, Efficiency, HCL, COVID-19, Zebra Technologies, Boston Dynamics, Control, Maintenance, Data analysis, Software AG, CAGR, IBM, Telstra, Transport, Algorithm, IOT, Power, Risk management, Renewable energy, Oil, Microsoft, Cisco Systems, Intel, Oracle, Huawei

DUBAI, UAE, March 2, 2022 /PRNewswire/ -- According to a recent analysis issued by FMI, the IoT in manufacturing market share is likely to reach US$ 399.08 billion by 2026, up from US$ 175.3 billion in 2020, accounting for 14.5% CAGR through 2022-2032. The ecosystem's diversity of significant stakeholders has resulted in a competitive and diversified adoption of IoT in manufacturing market. The Internet of Things enables industrial units to automate their operations, which results in cost savings, faster time to market, mass customisation, and increased safety.

Key Points: 
  • A comprehensive analysis on the IoT in Manufacturing market by Future Market Insights (FMI) provides in-depth insights into governing factors elevating the demand in the market.
  • The ecosystem's diversity of significant stakeholders has resulted in a competitive and diversifiedadoption of IoT in manufacturing market.
  • The Internet of Things enables industrial units to automate their operations, which results in cost savings, faster time to market, mass customisation, and increased safety.
  • The increasing demand for agile operations and production efficiency, as well as the exposure of intelligent machine applications, are expected to aid the IoT in manufacturing market's expansion.

IoT in Manufacturing Market growing at a CAGR of 14.50% over 2022-2032, at to reach USD 399.08 billion by 2026, Says FMI

Retrieved on: 
Wednesday, March 2, 2022
PTC, Adoption, Schneider Electric, IO, Software, Siemens, Computer, Machine learning, Automation, Research, SAP, Internet, Solution, Government, Safety, Aviation, Component, Boston, Bosch, FMI, ATOS, Efficiency, HCL, COVID-19, Zebra Technologies, Boston Dynamics, Control, Maintenance, Data analysis, Software AG, CAGR, IBM, Telstra, Transport, Algorithm, IOT, Power, Risk management, Renewable energy, Oil, Microsoft, Cisco Systems, Intel, Oracle, Huawei

DUBAI, UAE, March 2, 2022 /PRNewswire/ -- According to a recent analysis issued by FMI, the IoT in manufacturing market share is likely to reach US$ 399.08 billion by 2026, up from US$ 175.3 billion in 2020, accounting for 14.5% CAGR through 2022-2032. The ecosystem's diversity of significant stakeholders has resulted in a competitive and diversified adoption of IoT in manufacturing market. The Internet of Things enables industrial units to automate their operations, which results in cost savings, faster time to market, mass customisation, and increased safety.

Key Points: 
  • A comprehensive analysis on the IoT in Manufacturing market by Future Market Insights (FMI) provides in-depth insights into governing factors elevating the demand in the market.
  • The ecosystem's diversity of significant stakeholders has resulted in a competitive and diversifiedadoption of IoT in manufacturing market.
  • The Internet of Things enables industrial units to automate their operations, which results in cost savings, faster time to market, mass customisation, and increased safety.
  • The increasing demand for agile operations and production efficiency, as well as the exposure of intelligent machine applications, are expected to aid the IoT in manufacturing market's expansion.